To investigate the role of immune response in the antitumor activity of EGFR-TKI, we developed a syngeneic genetically engineered mouse (GEM) model of lung cancer driven by loss of Trp53 and expression of exon 19del/T790M EGFR (designated as PE) (Figure 1A). This evidence concerns the gene EGFR and lung cancer.